NO320733B1 - Anvendelse av noytrofil-funksjons-inhibitorer for fremstilling av preparater for medisinsk behandling - Google Patents
Anvendelse av noytrofil-funksjons-inhibitorer for fremstilling av preparater for medisinsk behandling Download PDFInfo
- Publication number
- NO320733B1 NO320733B1 NO20013535A NO20013535A NO320733B1 NO 320733 B1 NO320733 B1 NO 320733B1 NO 20013535 A NO20013535 A NO 20013535A NO 20013535 A NO20013535 A NO 20013535A NO 320733 B1 NO320733 B1 NO 320733B1
- Authority
- NO
- Norway
- Prior art keywords
- glucosamine
- neutrophils
- neutrophil
- preparation
- preparations
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 17
- 210000000440 neutrophil Anatomy 0.000 title description 61
- 239000003112 inhibitor Substances 0.000 title description 13
- 150000002301 glucosamine derivatives Chemical class 0.000 claims description 38
- 208000023504 respiratory system disease Diseases 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims description 7
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 7
- 229960002442 glucosamine Drugs 0.000 claims description 7
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims description 7
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims 1
- 229960002849 glucosamine sulfate Drugs 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229920000392 Zymosan Polymers 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- -1 glucosamine glucosamine salt Chemical class 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001064646A JP2002265365A (ja) | 2001-03-08 | 2001-03-08 | 好中球機能抑制剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20013535D0 NO20013535D0 (no) | 2001-07-17 |
| NO20013535L NO20013535L (no) | 2002-09-09 |
| NO320733B1 true NO320733B1 (no) | 2006-01-23 |
Family
ID=18923435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013535A NO320733B1 (no) | 2001-03-08 | 2001-07-17 | Anvendelse av noytrofil-funksjons-inhibitorer for fremstilling av preparater for medisinsk behandling |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6627621B2 (ja) |
| EP (1) | EP1238669B1 (ja) |
| JP (1) | JP2002265365A (ja) |
| KR (2) | KR20020072173A (ja) |
| CN (1) | CN1222295C (ja) |
| DE (1) | DE60104977T2 (ja) |
| NO (1) | NO320733B1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI301188B (en) | 2002-08-30 | 2008-09-21 | Sanyo Electric Co | Refrigeant cycling device and compressor using the same |
| US7943598B2 (en) | 2004-08-06 | 2011-05-17 | Bioiberica, S.A. | Use of organic glucosamine salts |
| SG173014A1 (en) | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
| UA110325C2 (en) * | 2009-07-03 | 2015-12-25 | Australian Biomedical Company Pty Ltd | Medicinal carbohydrates for treating respiratory conditions |
| EP2496592A1 (en) * | 2009-11-05 | 2012-09-12 | Pharma Base India Pvt. Ltd. | Process for preparing a mixed salt of glucosamine sulfate and a alkali metal chloride |
| US9052315B2 (en) | 2012-05-09 | 2015-06-09 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
| US10359614B2 (en) | 2012-07-03 | 2019-07-23 | Advanced Animal Diagnostics, Inc. | Diagnostic apparatus |
| US9816982B2 (en) * | 2012-07-03 | 2017-11-14 | Advanced Animal Diagnostics, Inc. | Diagnostic apparatus |
| US9797893B2 (en) | 2013-05-09 | 2017-10-24 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1044707B (it) * | 1968-10-26 | 1980-04-21 | Rotta Research Lab | Procedimento per la preparazione di sali di glucosanina e preparati farmaceutici comprendenti detti sali di glucosamina come agenti attivi |
| CA2035841C (en) * | 1990-02-22 | 1996-02-13 | Harry B. Demopoulos | Storage-stable glucosamine sulphate oral dosage forms and methods for their manufacture |
| JP3587665B2 (ja) * | 1997-09-19 | 2004-11-10 | 甲陽ケミカル株式会社 | グルコサミン塩含有ドリンク剤 |
| IT1298214B1 (it) * | 1998-01-28 | 1999-12-20 | Dompe Spa | Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche. |
| US6476005B1 (en) * | 1998-03-24 | 2002-11-05 | George D. Petito | Oral and injectable nutritional composition |
| WO1999052528A1 (en) * | 1998-04-11 | 1999-10-21 | Errekappa Euroterapici S.P.A. | Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application |
| JP4178584B2 (ja) * | 1998-04-24 | 2008-11-12 | 株式会社Ｊ−オイルミルズ | 抗アレルギー剤 |
-
2001
- 2001-03-08 JP JP2001064646A patent/JP2002265365A/ja not_active Abandoned
- 2001-07-16 KR KR1020010042899A patent/KR20020072173A/ko not_active Application Discontinuation
- 2001-07-17 DE DE60104977T patent/DE60104977T2/de not_active Expired - Lifetime
- 2001-07-17 NO NO20013535A patent/NO320733B1/no not_active IP Right Cessation
- 2001-07-17 EP EP01116700A patent/EP1238669B1/en not_active Expired - Lifetime
- 2001-07-18 CN CNB01125453XA patent/CN1222295C/zh not_active Expired - Fee Related
- 2001-07-18 US US09/906,771 patent/US6627621B2/en not_active Expired - Lifetime
-
2005
- 2005-06-29 KR KR1020050057062A patent/KR20050074425A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050074425A (ko) | 2005-07-18 |
| EP1238669B1 (en) | 2004-08-18 |
| KR20020072173A (ko) | 2002-09-14 |
| DE60104977D1 (de) | 2004-09-23 |
| US6627621B2 (en) | 2003-09-30 |
| US20020128230A1 (en) | 2002-09-12 |
| NO20013535D0 (no) | 2001-07-17 |
| DE60104977T2 (de) | 2005-08-18 |
| CN1374086A (zh) | 2002-10-16 |
| EP1238669A3 (en) | 2002-12-11 |
| CN1222295C (zh) | 2005-10-12 |
| EP1238669A2 (en) | 2002-09-11 |
| NO20013535L (no) | 2002-09-09 |
| JP2002265365A (ja) | 2002-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6407141B1 (en) | Oxalic acid or oxalate compositions and methods for vascular disorders, diseases, and calcerous conditions | |
| KR101870846B1 (ko) | 다기능성 조성물 및 이의 제조 방법과 용도 | |
| US20050171056A1 (en) | Sodium ion absorption inhibitors, and preventive and therapeutic agents and foods containing the same | |
| KR20050074425A (ko) | 호중구 기능 억제용 음료수 또는 음식 | |
| EP0053175B1 (en) | Use of d-fenfluramine for the manufacture of a medicament for modifying feeding behavior | |
| Lehane | Paralytic shellfish poisoning: a potential public health problem | |
| CN112057605A (zh) | 一种海洋胶原低聚肽及其制备方法 | |
| EP4034122A1 (en) | Methods for treating hyperphenylalaninemia | |
| JP2002154967A (ja) | 糖尿病治療剤 | |
| US6448232B1 (en) | Method of using dihydrochalcone derivatives to block glucose transfer | |
| JP4723320B2 (ja) | 血中レプチン濃度上昇剤 | |
| US5773426A (en) | Proteoglucan and antidiabetic drug thereof | |
| US20100069305A1 (en) | Composition for maintaining gastrointestinal homeostasis | |
| JPWO2018179441A1 (ja) | インスリン抵抗性の悪化予防または改善剤 | |
| US5436004A (en) | Administration of cholesterol reductase to humans | |
| JPH0995448A (ja) | 血中ビオチン濃度の増加方法およびビオチン含有飲食品 | |
| WO2006085523A1 (ja) | 血糖値上昇抑制用組成物 | |
| JP2014172902A (ja) | Ｌａｃｔｏｂａｃｉｌｌｕｓｐｌａｎｔａｒｕｍを用いたアカモク発酵物の糖尿病態改善剤 | |
| US10961176B2 (en) | Compound hexadecaphlorethol isolated from Ishige okamurae and use thereof | |
| KR20040097813A (ko) | 식욕억제, 체지방 감소 및 배변 활성화등 3가지 기능을 갖는 항비만 기능성 조성물 | |
| EP1043022B1 (en) | Sodium ion absorption inhibitors and sodium ion excretion accelerators as preventive and therapeutic agents for diseases resulting from excessive intake of common salt | |
| US7704974B2 (en) | Method for the treatment and/or prevention of urinary disorders | |
| CN104208691A (zh) | 组合物在制备减肥产品中的应用 | |
| CN104146995B (zh) | 11-氧乙酰鸟巢烷三醇在制备预防和/或治疗胃溃疡药物中的应用 | |
| JP6145351B2 (ja) | 納豆菌を用いたマコンブ発酵物の糖尿病態改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |